Aflac Incorporated (NYSE:AFL) Shares Sold by Forza Wealth Management LLC

Forza Wealth Management LLC cut its stake in Aflac Incorporated (NYSE:AFL) by 3.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,270 shares of the financial services provider’s stock after selling 740 shares during the period. Aflac makes up approximately 0.9% of Forza Wealth Management LLC’s investment portfolio, making the stock its 28th biggest position. Forza Wealth Management LLC’s holdings in Aflac were worth $1,826,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in AFL. Vanguard Group Inc. raised its position in Aflac by 1.1% in the third quarter. Vanguard Group Inc. now owns 54,208,007 shares of the financial services provider’s stock worth $4,160,465,000 after acquiring an additional 605,210 shares in the last quarter. Morgan Stanley raised its holdings in shares of Aflac by 9.0% in the 3rd quarter. Morgan Stanley now owns 9,643,531 shares of the financial services provider’s stock worth $740,141,000 after purchasing an additional 794,784 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Aflac by 5.3% in the 3rd quarter. Northern Trust Corp now owns 7,295,810 shares of the financial services provider’s stock worth $559,953,000 after purchasing an additional 368,704 shares in the last quarter. Invesco Ltd. lifted its stake in Aflac by 5.0% during the third quarter. Invesco Ltd. now owns 4,808,289 shares of the financial services provider’s stock valued at $369,036,000 after purchasing an additional 227,516 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Aflac by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,190,954 shares of the financial services provider’s stock worth $263,254,000 after buying an additional 17,892 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

Insider Activity at Aflac

In other news, Director Arthur Reginald Collins sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $79.73, for a total transaction of $239,190.00. Following the transaction, the director now owns 5,592 shares in the company, valued at approximately $445,850.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Aflac news, Director Masatoshi Koide sold 30,493 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the sale, the director now owns 86,090 shares of the company’s stock, valued at $6,879,451.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur Reginald Collins sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $79.73, for a total value of $239,190.00. Following the transaction, the director now owns 5,592 shares in the company, valued at approximately $445,850.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,493 shares of company stock valued at $3,765,706. 0.90% of the stock is currently owned by corporate insiders.

Aflac Stock Up 1.1 %

Shares of Aflac stock traded up $0.93 on Monday, hitting $84.54. 2,001,632 shares of the company traded hands, compared to its average volume of 2,269,864. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. Aflac Incorporated has a 12-month low of $64.10 and a 12-month high of $86.26. The company has a 50-day moving average price of $82.79 and a 200 day moving average price of $81.82. The company has a market cap of $48.64 billion, a PE ratio of 10.91, a PEG ratio of 2.29 and a beta of 0.91.

Aflac (NYSE:AFL) last issued its earnings results on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The firm had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same quarter last year, the firm earned $1.29 EPS. Sell-side analysts predict that Aflac Incorporated will post 6.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on AFL shares. StockNews.com cut Aflac from a “hold” rating to a “sell” rating in a report on Wednesday, April 10th. Raymond James upped their target price on Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI cut Aflac from an “in-line” rating to an “underperform” rating and lifted their price target for the stock from $76.00 to $78.00 in a research note on Thursday, January 4th. The Goldman Sachs Group upped their price objective on shares of Aflac from $61.00 to $75.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Finally, Piper Sandler lifted their target price on shares of Aflac from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, April 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Aflac presently has a consensus rating of “Hold” and an average target price of $82.15.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.